Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study)

Ophthalmology

Volumn 123, Issue 6, 2016, Pages 1399-1401

  Fraser Bell, Samantha ^a   Lim, Lyndell L ^b   Campain, Anna ^a   Mehta, Hemal ^a   Aroney, Christine ^a   Bryant, Jaclyn ^a   Li, Ji ^a   Quin, Godfrey J ^a,c   McAllister, Ian L ^d   Gillies, Mark C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID;

CATARACT EXTRACTION; CENTRAL MACULAR THICKNESS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; ENDOPHTHALMITIS; HUMAN; IMPLANT; INTRAOCULAR PRESSURE; KERATOPATHY; MAJOR CLINICAL STUDY; NOTE; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; SLOW RELEASE FORMULATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; COMPLICATION; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG IMPLANT; FEMALE; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; TIME FACTOR; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DEXAMETHASONE; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84953432483     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.12.012     Document Type: Article

References (5)

1. H. Mehta, M. Gillies, and S. Fraser-Bell Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema Ther Adv Chronic Dis 6 2015 234 245
2. M.C. Gillies, L.L. Lim, A. Campain, and et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study Ophthalmology 121 2014 2473 2481
3. R. Rajendram, S. Fraser-Bell, A. Kaines, and et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3 Arch Ophthalmol 130 2012 972 979
4. M.J. Elman, N.M. Bressler, H. Qin, and et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 118 2011 609 614
5. H. Mehta, S. Fraser-Bell, A. Yeung, and et al. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial Br J Ophthalmol 2015 Nov 4 10.1136/bjophthalmol-2015-307797 pii: bjophthalmol-2015-307797 [Epub ahead of print]